← Back to Search

Monoclonal Antibodies

Investigational Alzheimer's Drugs for Early Onset Alzheimer's Disease (DIAN-TU Trial)

Phase 2 & 3
Waitlist Available
Research Sponsored by Washington University School of Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Individuals who know they have an Alzheimer's disease-causing mutation
Adequate visual and auditory abilities to perform all aspects of the cognitive and functional assessments
Must not have
History or presence of clinically significant cardiovascular disease, hepatic/renal disorders, infectious disease or immune disorder, or metabolic/endocrine disorders
Positive urine or serum pregnancy test or plans or desires to become pregnant during the course of the trial
Timeline
Screening 3 weeks
Treatment Varies
Follow Up weeks 24, 52, 104, 156 and 208
Awards & highlights

Summary

This trial tests two drugs, lecanemab and E2814, in people with a genetic mutation that causes Alzheimer's disease. Lecanemab helps remove harmful protein clumps from the brain, while E2814 prevents harmful protein tangles from forming. The goal is to see if these drugs can slow down or improve symptoms of Alzheimer's.

Who is the study for?
This trial is for individuals aged 18-80 who have a genetic mutation causing early onset Alzheimer's, are within -10 to +10 years of their predicted age of symptom onset, and can perform required tests (MRI, LP, PET). They must be cognitively normal or mildly impaired and have a reliable study partner. Women must use contraception if applicable.
What is being tested?
The trial is testing Lecanemab and E2814 against a placebo to see if they improve Alzheimer's biomarkers and slow cognitive decline. Participants will receive either the investigational drugs or placebo to assess safety, tolerability, and effectiveness.
What are the potential side effects?
Potential side effects may include reactions at the injection site, headache, fatigue, allergic responses or infusion-related reactions. Side effects vary by individual; some may experience none while others could have more severe reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I know I carry a gene mutation linked to Alzheimer's disease.
Select...
I can see and hear well enough to complete tests.
Select...
I am between 18 and 80 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I do not have significant heart, liver, kidney, infectious, immune, or hormonal diseases.
Select...
I am not pregnant and do not plan to become pregnant during the trial.
Select...
I am not on blood thinners, except for low-dose aspirin.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~weeks 24, 52, 104, 156 and 208
This trial's timeline: 3 weeks for screening, Varies for treatment, and weeks 24, 52, 104, 156 and 208 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
The primary end point is the change from Week 24 to Week 104 and Week 208 in tau PET in the Symptomatic Population (Cohort 1).
Secondary study objectives
Asymptomatic Population (Cohort 2): Key Secondary: Change from Week 0 to Week 104 and Week 208 in CSF ptau217/total tau
Symptomatic Population (Cohort 1): Key Secondary: Change from Week 24 to Week 208 in Clinical Dementia Scale - Sum of Boxes (CDR-SB).

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: E2814 plus lecanemabExperimental Treatment2 Interventions
Symptomatic Population (Cohort 1) At Week 0, participants will receive open-label lecanemab administered intravenously for the full treatment period. At Week 24, participants randomized to E2814 will receive intravenously in a blinded fashion for the remainder of their treatment period. Asymptomatic Population (Cohort 2) At Week 0, participants randomized to E2814 will receive intravenously in a blinded fashion for the full treatment period. At Week 52, all participants will initiate open-label lecanemab administered intravenously for the remainder of their treatment period.
Group II: Matching placebo (E2814) plus lecanemabPlacebo Group2 Interventions
Symptomatic Population (Cohort 1) At Week 0, participants will receive open-label lecanemab administered intravenously for the full treatment period. At Week 24, participants randomized to E2814 placebo will receive placebo intravenously in a blinded fashion for the remainder of their treatment period. Asymptomatic Population (Cohort 2) At Week 0, participants randomized to E2814 placebo will receive placebo intravenously in a blinded fashion for the full treatment period. At Week 52, all participants will initiate open-label lecanemab administered intravenously for the remainder of their treatment period.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
E2814
2019
Completed Phase 2
~80
Lecanemab
Not yet FDA approved

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Anti-amyloid monoclonal antibodies, such as those targeting amyloid-beta (Aβ) plaques, work by binding to various forms of Aβ (monomers, oligomers, plaques) and promoting their clearance from the brain. This mechanism is crucial for Alzheimer's Disease patients because the accumulation of amyloid plaques is linked to neurodegeneration and cognitive decline. By reducing these plaques, these treatments aim to slow disease progression and improve cognitive outcomes.
Lessons Learnt from the Second Generation of Anti-Amyloid Monoclonal Antibodies Clinical Trials.

Find a Location

Who is running the clinical trial?

Washington University School of MedicineLead Sponsor
1,974 Previous Clinical Trials
2,308,980 Total Patients Enrolled
Alzheimer's AssociationOTHER
96 Previous Clinical Trials
42,133 Total Patients Enrolled
National Institute on Aging (NIA)NIH
1,751 Previous Clinical Trials
28,123,618 Total Patients Enrolled

Media Library

E2814 (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT05269394 — Phase 2 & 3
Alzheimer's Disease Research Study Groups: E2814 plus lecanemab, Matching placebo (E2814) plus lecanemab
Alzheimer's Disease Clinical Trial 2023: E2814 Highlights & Side Effects. Trial Name: NCT05269394 — Phase 2 & 3
E2814 (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05269394 — Phase 2 & 3
~108 spots leftby Apr 2028